latest news and events from Oncotherics
Tuesday, 29 November 2016
OncoTherics wins Innovate UK Global Feasibility Study Award
OncoTherics wins Innovate UK Global Feasibility
Study Award. Project Title: Exploiting Tumour Hypoxia in Precision
Medicine: Advancing Novel Prodrug
Therapies for Pancreatic Cancer with PMCC, a World-leading Canadian Cancer
Centre. As part of the award, OncoTherics
will work with Alan Boyd Consultancy to explore a regulatory strategy for its novel hypoxia activated pro-drugs.
Tuesday, 1 November 2016
OCT1002 shows promising results in prostate cancer research
Researchers at Ulster University have just published the latest results of a three-year study looking at OCT1002 in combination with hormone therapy in prostate cancer.
The research programme was supported by Prostate Cancer UK through a £213,000 grant from the Movember Foundation and the latest results have been published in the Journal of Clinical Cancer Research
CLICK HERE to link to the paper.
CLICK HERE to hear Dr Declan McKenna speaking on ITV news about the exciting results.
CLICK HERE to link to the paper.
CLICK HERE to hear Dr Declan McKenna speaking on ITV news about the exciting results.
Sunday, 22 May 2016
OncoTherics VOOM's awareness for Pancreatic Cancer!
Over 400 people from around the world have voted for OncoTherics in the VOOM 2016 challenge!
The VOOM 2016 challenge invites small and start-up businesses to canvass votes to qualify for a chance to pitch to Richard Branson.
OncoTherics has used the competition to raise awareness of Pancreatic Cancer and the lack of investment in new therapeutics that can make a difference to overall survival and quality of life.
More thank 10,000 businesses have entered the competition and at the time of writing, OncoTherics is ranked at number 106 in the Grow category!!
The OncoTherics Team would like to say a huge THANK YOU to all who have voted - your vote has helped raise awareness about Pancreatic Cancer and the real challenges that this disease poses.
The VOOM 2016 challenge invites small and start-up businesses to canvass votes to qualify for a chance to pitch to Richard Branson.
OncoTherics has used the competition to raise awareness of Pancreatic Cancer and the lack of investment in new therapeutics that can make a difference to overall survival and quality of life.
More thank 10,000 businesses have entered the competition and at the time of writing, OncoTherics is ranked at number 106 in the Grow category!!
The OncoTherics Team would like to say a huge THANK YOU to all who have voted - your vote has helped raise awareness about Pancreatic Cancer and the real challenges that this disease poses.
Monday, 7 March 2016
Dr Thomas Morris joins OncoTherics as Chief Medical Officer
OncoTherics is delighted to announce the appointment of Dr Thomas Morris as the company's new Director and Chief Medical Officer.
Dr Morris has worked in drug development for over 20 years with much of this time specialising in oncology. He joins OncoTherics after a long and successful career at AstraZeneca where he has held a number of senior global R&D roles. Most recently these include Senior Medical Director, Executive Director Clinical Programs and Medical Science Director.
Dr Morris has overseen the clinical development of several global drug programs, interacting with academic groups and regulatory agencies worldwide. He brings a considerable wealth of experience to OncoTherics and will lead the company's clinical trial programme.
Dr Morris has worked in drug development for over 20 years with much of this time specialising in oncology. He joins OncoTherics after a long and successful career at AstraZeneca where he has held a number of senior global R&D roles. Most recently these include Senior Medical Director, Executive Director Clinical Programs and Medical Science Director.
Dr Morris has overseen the clinical development of several global drug programs, interacting with academic groups and regulatory agencies worldwide. He brings a considerable wealth of experience to OncoTherics and will lead the company's clinical trial programme.
Subscribe to:
Posts (Atom)